Valuation: BioTime, Inc.

Market Cap 319M 280M 258M 241M 453M 30.1B 462M 3.1B 1.2B 14.88B 1.2B 1.17B 51.59B P/E 2026 *
-18.3x
P/E 2027 * -14x
Enterprise Value 319M 280M 258M 241M 453M 30.1B 462M 3.1B 1.2B 14.88B 1.2B 1.17B 51.59B EV / Sales 2026 *
17.8x
EV / Sales 2027 * 17.6x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Operating Officer - 01/12/2010
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 68 11/04/2014
Chairman 60 27/04/2024
Change 5-day change 1-year change 3-year change Capi.($)
+7.37%-11.55% - - 319M
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +1.48%+9.14%+76.18%+119.90% 25.57B
Weighted average by Cap. +0.76%+8.71%+86.69%+140.75%

Financials

2026 *2027 *
Net sales 17.94M 15.73M 14.5M 13.57M 25.45M 1.69B 25.98M 174M 67.42M 836M 67.35M 65.88M 2.9B 18.09M 15.86M 14.62M 13.69M 25.67M 1.71B 26.2M 176M 68.01M 844M 67.94M 66.46M 2.92B
Net income -23.79M -20.86M -19.23M -18M -33.75M -2.24B -34.45M -231M -89.42M -1.11B -89.32M -87.37M -3.85B -31.66M -27.76M -25.59M -23.96M -44.92M -2.99B -45.85M -308M -119M -1.48B -119M -116M -5.12B
Net Debt - -
Logo BioTime, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-